ArticleGenome medicine2026
Geospatial genetic evolution and phenotypic plasticity in triple-negative breast cancer.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geospatial genetic evolution and phenotypic plasticity in triple-negative breast cancer.Genome medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundThe interplay between genotype and phenotype in shaping spatial heterogeneity and metastatic evolution in triple-negative breast cancer (TNBC) remains poorly understood.
methodsHere, we developed a pathology-guided geospatial genomic and transcriptomic sequencing workflow (pGeo-G&T-seq) and applied it to TNBC specimens from primary tumors and matched metastatic sites. Using laser capture microdissection (LCM) we isolated mRNA and gDNA for whole-exome sequencing, whole-genome sequencing and whole-transcriptome sequencing to analyze spatial genomic heterogeneity and transcriptomic plasticity. Findings were further evaluated using independent bulk transcriptomic, single-cell immunotherapy, and spatial transcriptomic TNBC datasets.
resultsThe analysis unveiled spatial intratumoral heterogeneity at genomic and transcriptomic levels characterized by distinct spatial patterns of "decay" or "uniformity", demonstrating regional clonal expansion and genetic mosaicism, including heterogeneity in driver alterations and molecular subtypes. Notably, we identified a previously uncharacterized oxidative phosphorylation (OXPHOS)-associated transcriptional state associated with poor prognosis and features of limited immunotherapy responsiveness in single-cell cohorts. Intriguingly, genetic ancestry was associated with relatively stable transcriptional programs in a subset of cases. Furthermore, phylogenetically closely related clones from primary tumors and lymph node metastases shared convergent biological processes, suggesting that phenotypic traits may be partially retained during metastatic colonization.
conclusionsThese findings support a model in which genetic evolution and phenotypic retention contribute to the spatial heterogeneity and metastatic progression of TNBC. More broadly, our pathology-guided spatial multi-omics framework enables the dissection of genotype-phenotype coupling in intact tissue, while the identification of an OXPHOS-associated transcriptional program may inform biologically guided patient stratification and generate hypotheses for future therapeutic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.